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Abstract
High level MYC expression is associated with almost all human cancers. JQ1, a chemical compound that inhibits MYC
expression is therapeutically effective in preclinical animal models in midline carcinoma, and Burkitt’s lymphoma (BL). Here
we show that JQ1 does not inhibit MYC expression to a similar extent in all tumor cells. The BL cells showed a ,90%
decrease in MYC transcription upon treatment with JQ1, however, no corresponding reduction was seen in several non-BL
cells. Molecularly, these differences appear due to requirements of Brd4, the most active version of the Positive
Transcription Elongation Factor B (P-TEFb) within the Super Elongation Complex (SEC), and transcription factors such as
Gdown1, and MED26 and also other unknown cell specific factors. Our study demonstrates that the regulation of high levels
of MYC expression in different cancer cells is driven by unique regulatory mechanisms and that such exclusive regulatory
signatures in each cancer cells could be employed for targeted therapeutics.
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Introduction
Lymphomas are broadly classified into two categories: Hodg-
kin’s and non-Hodgkin’s lymphoma (NHL) [1]. The two most
common forms of aggressive NHL are diffuse large B cell
lymphoma (DLBCL) and Burkitt’s lymphoma (BL) [1,2,3].
Translocation of the proto-oncogene MYC into one of the
immunoglobulin gene loci [IG-MYC translocation; mostly of the
t(8;14)q24;q32 type] resulting in aberrant MYC expression is
regarded as the dominant genetic event in the genesis of BL and
about 10% of DLBCL [4]. Besides translocation, MYC can
undergo oncogenic deregulation via high-level gene amplification
as well as mutations in cis-regulatory elements in several cancer
types (e.g., myeloma, colon carcinoma and neuroblastoma) [5,6].
Moreover, while most BLs have deregulated c-MYC (henceforth
referred to as MYC) expression as a consequence of an IG-MYC
translocation, the majority of non-BLs do not carry IG-MYC
translocations, but other genetic abnormalities leading to dereg-
ulated MYC expression. Though high expression is restricted to
BLs, MYC target expression varies on a lower level across non-BL
and intermediate lymphomas and constitutes a negative prognostic
marker in these lymphomas.
MYC dimerizes with MAX to bind its target sequence (E-box)
and regulate gene expression. MYC not only activates transcrip-
tion but also represses target gene expression either via direct
biding (with Miz-1 transcription factor) or via regulation of micro-
RNAs (miRs) [7]. However, the function of MYC is complicated
as two recent studies show that MYC does not have a specific
transcriptional signature but serves to amplify the output of
existing transcriptional programs in a given cell rather than
executing its own transcriptional program [8,9].
MYC belongs to a class of genes called Primary Response Genes
(PRGs) many of which harbor paused Pol II at the proximal
promoter area that upon activation can quickly switch to an
elongating Pol II and functional transcription [10]. Signal
dependent stimulation results in enhanced acetylation at histone
3 lysine 14 (H3K14Ac) and either of two H4 lysine pairs, H4K5/
12 or H4K8/16, an event which appears crucial for the binding of
bromodomain (BRD) proteins that recruit transcription factors
necessary for transcription [11,12]. Recruitment of positive
transcription elongation factor b (P-TEFb), and possibly the
general initiation cofactor Mediator, plays an important role in
Brd4-regulated transcription of many genes including MYC.
Indeed, after recruitment by Brd4, P-TEFb phosphorylates the
elongation factors DSIF (Spt4 and Spt5), negative elongation
factor (NELF), and Pol II resulting in release of paused Pol II and
subsequent elongation of transcription [10,13] and recently
reviewed in [14]. Collectively, these and other results suggest that
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elongation of transcription is a critical regulatory point in
orchestrating MYC regulation [10].
As many MYC-driven processes are required for homeostasis
and growth, therapeutic strategies geared towards modulation of
MYC expression rather than outright suppression seem attractive.
The Mitsubishi Tanabe Pharma Corporation first described
thienodiazepine analogs that potently inhibit chromatin binding
of bromodomains related to the BET family [15]. Subsequently, a
closely related small molecule inhibitor, JQ1, has been found to be
therapeutically effective in pre-clinical animal models [16,17,18].
These and related small molecules competitively occupy the
acetyl-binding pockets of BET bromodomains, resulting in release
of BET proteins (in particular Brd4) from chromatin [19]. Despite
these promising demonstrations, JQ1 does not inhibit MYC
expression to a similar extent in all tumor cells [19]. Thus, it is
important to understand why JQ1 is effective in only certain MYC-
dependent cancers, which may ultimately determine clinical
efficacy of this compound in patients.
We observed that although JQ1 treatment decreased Brd4
occupancy to a similar degree in the cell types tested, the ability of
JQ1 to reduce MYC transcription between cells differed. In JQ1-
sensitive cells, inhibition occurred at the level of nascent
transcription affecting Pol II, ‘‘paused’’ Pol II-Ser5-P, ‘‘elongat-
ing’’ Pol II-Ser2-P, and P-TEFb occupancy. Furthermore, there is
a difference in the occupancy of members of the Super Elongation
Complex (SEC), and factors associated with RNA Polymerase II,
at MYC promoter regions in the two cell types. Collectively, our
data indicate high levels of MYC are maintained in different cancer
cells via distinct mechanisms at the level of transcription
elongation with different compliments of transcription factors
and are therefore subjected to different JQ1 sensitivity.
Materials and Methods
Cell Culture
The mature mouse B cell lymphoma BAL17 [20], human BL
lines Akata [21], Raji [22], and Ramos [23], and human epithelial
line HeLa-S3 [24] were cultured in RPMI media with HEPES
(Invitrogen) supplemented with 100 U/ml Penicillin, 100 mg/ml
Streptomycin, 1 mM Sodium Pyruvate, 0.5 mM 2-Mercaptoeth-
anol solution (Invitrogen) and 10% Fetal Calf Sera (Atlanta
Biologicals). RNA based assays used 1–26106 cells and 26107 cells
were used for Chromatin Immunoprecipitation (ChIP). JQ1,
solubilized in DMSO, was diluted into media at 1 mM and
incubated with cells for 2 hours at 37uC. No effects on
transcription were observed with DMSO controls (data not
shown). Experiments shown in Figure S1 (File S1) involving
BCR stimulation consisted of a 2 hr pre-treatment with 1 mM JQ1
followed by 30 minutes of exposure to antibody fragments specific
for either human or mouse BCR (Jackson Immunoresearch).
RNA-Real Time PCR Analysis
Performed as previously described [25]. Ct values were
averaged and the signal reported as the ratio of target over ActB
Figure 1. Effects of JQ1 on MYC expression. BAL17 (Murine B cell), Human HeLa, and Human BL Raji cells and either untreated or treated with
1 mM of JQ1 for 2 hours. (A) mRNA analysis was performed in triplicate, reported relative to ActB mRNA expression and is shown as the average and
standard deviation of three experiments. (B) Detection of primary transcription by PCR amplification using primers across internal exon/intron
borders of MYC was performed three times and reported relative to ActB mRNA expression. (C) Strand-specific transcription was detected by strand
specific reverse transcription amplification as detailed in Material and Methods followed by standard PCR methods. These experiments were
performed twice.
doi:10.1371/journal.pone.0087003.g001
Myc Regulation
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mRNA via linear equations specific to each primer pair. Myc
primers are listed in S3 (File S1) unless shown below.
mRNA Primers-mouse
Myc Primers not listed in Figure S3 (File S1)
In1/Ex1 59-AGAGCTCCTCGAGCTGTTTG
59-CGTCTACATTCAAGACGCAGA
mRNA Primers Human
Myc Primers not listed in Figure S3 (File S1)
In1/Ex2 59-GCACCAAGACCCCTTTAACTC
Western Blotting
Nuclear extracts from 26106 cells were subjected to 10% (Myc)
or 6% (Brd4) SDS-PAGE followed by Western blotting. Primary
antibodies (rabbit anti-C-terminal Brd4-C IgG and rabbit anti-
Brd4-S484/488-phos) [26,27], rabbit anti-CREB IgG (Cell
signaling) and secondary (goat anti-rabbit horseradish peroxi-
dase-linked IgG, Invitrogen) antibodies at 1:1500. Blots were
visualized with the Novex ECL chemo-luminescent Substrate
Regent Kit (Invitrogen) and densitometry performed with the
ChemiDoc MP Imaging System (Biorad).
Strand-specific Detection
380 ng of RNA with 1 mM final primer concentration were
employed for each RT reaction using Invitrogen’s Cloned AMV
First Strand synthesis kit. Strand-specific primers; for (+) strand the
reverse primers corresponding to the TSS area (+17 for mouse and
+11 for human) and for (2) strand forward primers corresponding
to the end of the gene (+3948 for mouse and +4791 for human,
sequences in Figure S3, in File S1). Standard real-time PCR
Figure 2. Brd4 occupancy and expression in different cells. Cells were either untreated or treated with 1 mM of JQ1 for 2 hours. (A) Chromatin
Immunoprecipitation (ChIP) across MYC with anti-C-terminal Brd4 antibody. Each experiment was performed twice, analyzed in triplicate via real-time
PCR and reported as the mean and standard deviation of the two experiments. A representation of the promoter area of MYC is provided for
orientation. (B) Western blotting to detect (far left) Brd4 (,180 KD) and (middle) Brd4-S484/488-phos (P-Brd4, ,220 KD) was performed three times.
A non-specific band detected with phopsho-Brd4 antibody is denoted with an asterisk. Typical results are shown with densitometry analysis relative
to CREB expression, which is used as a normalization control (far right).
doi:10.1371/journal.pone.0087003.g002
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ActB   59-AGGCATGGAGTCCTGTGGTATC            
  59-AGCCACAGGTCCTAAGGCCAG.
Fos     59-GGATTTGACTGGAGGTCTG
    59- TGGGCTCAGGGTCGTTGA
59-TCCTGTTGGTGAAGCTAACGEx2/In2 5'-AG
CGACTCTGGTAAGCGAAG
59-GTGGCCCGTTAAATAAGCTG
ActB       59-CTCTTCCAGCCTTCCTTCCT     
      59-AGCACTGTGTTGGCGTACAG
Fos    59-CTCCGGTGGTCACCTGTACT
59-GTCAGAGGAAGGCTCATTGC
amplification of the was employed with the indicated primers and
their companions, shown in Figure S2 (File S1), and the resulting
Ct values were converted to relative ng and normalized to the
starting concentration of chromosomal RNA.
Chromatin Immunoprecipitation (ChIP)
A standard ChIP assay was performed and has been previously
described [25]. PCR primers and scheme are shown in Figure S3,
in File S1. Ct values were averaged and the signal represented as
% of input DNA via linear equations specific to each primer pair.
ChIP Antibodies
Rabbit polyclonal anti-mouse RNA Pol II (N-20, sc-899, Santa
Cruz), RNA Pol II-Ser5P mouse monoclonal (sc-47701, Santa
Cruz), RNA Pol II-Ser2P H5 mouse ascites (Covance),
H3K36me3 Rabbit polyclonal (ab9050, Abcam), anti-Cyclin T
rabbit polyclonal (H-245, sc-10750, Santa Cruz), rabbit anti-C-
terminal BRD4 IgG [27], MED26 mouse anti-MED26/CRSP7
(Ab50619, Abcam), Gdown1 sheep anti-Gdown1 IgG [28], anti-
AFF4 antibody [29] and anti-ELL2 antibody [29].
Sequencing Analysis
Figure S2 (File S1) shows sequencing data derived from
University of California Santa Cruz Genome Browser (UCSC
GB) tracks ‘‘wgEncodeUtaChIPseqBaseOverlapSignalHelas3-
Pol2’’ (HeLa S3) and GEO data set GSM920942 (Raji), mapped
to human genome build hg18. The University of California Santa
Cruz Genome Web Browser setting normalized to the highest
peak at the TSS.
Results
Differential JQ1 Sensitivity
We performed dose- and time-dependent testing of Brd4
inhibition with JQ1 and noted the effect on MYC transcription
in a variety of cells including HeLa-S3 cells, whose MYC
expression was reported [19] to be resistant to JQ1 treatment.
Shown in Fig. 1A, tested cell lines express MYC at high levels,
comparable to levels detected at the peak of primary naı¨ve resting
B cell induction (data not shown). Steady state mRNA levels of
MYC in a non-BL murine B cell lymphoma line (BAL17) that over
expresses MYC at levels similar to the BL cells and HeLa cells
showed no significant sensitivity to JQ1 (Fig. 1A). Both HeLa and
BAL17 cells continued this resistance at concentrations up to
5 mM (data not shown), while MYC RNA in BL cells was uniformly
decreased by ,90% when treated with 1 mM of JQ1 for a period
of two hours (Fig. 1A). BL cells are reported to express 2- to 5-fold
more MYC-specific RNA than B-cell lines without a translocation
[30]. Although Western blotting d indicate the Raji BL line
expresses more MYC protein, consistent with the mRNA data
(Fig. 1A), JQ1 treatment decreased MYC protein expression in
Raji but not HeLa and BAL17 (data not shown). Together these
results demonstrated that JQ1 resistance occurred in both non-
lymphoma and lymphoma cell lines representing both murine and
human species.
Because mRNA production may not necessarily correlate with
primary transcript production [25,31], we tested the effect of JQ1
on primary transcription. Analysis of primary transcript, per-
formed with primers against the exon/intron borders of MYC
(schematically represented in Supplemental Fig. 3 and/or listed in
Materials and Methods), showed that primary transcription
sensitivity to JQ1 was parallel to that of mRNA (Fig. 1B). Thus,
long, and presumably full-length, primary transcripts were either
resistant (BAL17 or HeLa) or sensitive (Raji) to JQ1. Therefore,
the difference in JQ1 responses correlated with primary transcrip-
tion and did not occur at the level of post-transcriptional
modification, such as splicing and mRNA or protein stability.
Divergent transcription is common of many promoters in
organisms and plays an important role in gene regulation [32].
Indeed, antisense transcription from the MYC locus has been
observed in several cell lines [33]. Because we only measured total
steady state RNA (Fig. 1A), whether differential JQ1 sensitivity
reflects differences in possible transcription originating from the 39
end was tested. Although antisense transcription in both BAL17
Figure 3. Effects of JQ1 on P-TEFb occupancy. BAL17 and Raji cells were either untreated or treated with 1 mM of JQ1 for 2 hours. Recruitment
of P-TEFb was detected by ChIP assays. Each experiment was analyzed in triplicate via real-time PCR, performed twice, and is reported as the mean
and standard deviation of the two experiments.
doi:10.1371/journal.pone.0087003.g003
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and HeLa cells was small in comparison to sense transcription, it
was largely unaffected by JQ1 (Fig. 1C, left and middle panels).
The wide difference in levels of sense and antisense transcripts
observed amongst different cell lines is currently unexplained but
might reflect a combination of transcriptional and post-transcrip-
tional effects. Regardless, like sense transcription, antisense
transcription originating from the MYC locus in Raji cells was
inhibited by JQ1 (Fig. 1C, right panel). Therefore, although more
antisense transcription was noted in Raji cells, the difference in
JQ1 sensitivity was not likely due to differences in antisense
transcripts.
JQ1 Leads to Decreased Brd4 Occupancy in Resistant and
Sensitive Cells
We observed that Brd4 recruitment was reduced by JQ1 in both
cell types–therefore, the difference in JQ1 sensitivity between
different cells was not due to permeability. We also observed that
Brd4 recruitment to the transcription start site (TSS) was roughly
2.5 fold more in Raji (+11) cells compared to BAL17 (+17)
(Fig. 2A). HeLa exhibited Brd4 recruitment and JQ1 sensitivity
similar to BAL17 (data not shown). Moreover, a significant
amount of Brd4 occupancy was noted across the body of MYC in
all the cells tested, though there was a higher level of coding region
occupancy in BAL17 cells. Though commonly associated with 59-
end enhancers and promoters, Brd4 has been shown to occupy the
coding region of PRGs such as c-fos and MYC [26].
Promoter recruitment of Brd4 requires phosphorylation at S484
and S488 and deletion of this region results in decreased CycT and
Pol II occupancy and transcription [26]. Consistent with the ChIP
assay, Western blotting showed a higher level of total Brd4 in Raji
nuclear extracts compared to HeLa and BAL17, although Brd4-
S484P/S488P in Raji cells was slightly less compared to BAL17
and HeLa (Fig. 2B). Interestingly, the P-BRD4 band in HeLa cells
migrated faster than either the Raji or BAL17 P-Brd4 band,
perhaps reflecting a slight difference in the extent or site of
phosphorylation. However, the difference in phosphorylated Brd4
(the active form) between different cells might not explain the
differences in JQ1 sensitivity.
Brd4 interacts with factors that either recruit Pol II to the site of
transcription or drive the transcriptional complex from pausing to
Figure 4. RNA Polymerase II occupancy in the absence and presence of JQ1. Cells were either untreated or treated with 1 mM of JQ1 for 2
hours. (A) Pol II was detected by antibody against the N-terminal of Pol II (B) Pol II Serine 5-P (C) Pol II Serine 2-P. Chromatin ChIP assays were
performed in duplicate. Each experiment was analyzed in triplicate via real-time PCR, performed twice, and is reported as the mean and standard
deviation of the two experiments.
doi:10.1371/journal.pone.0087003.g004
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the elongation mode (reviewed in [10]). Additionally, a reduction
of functional Brd4 resulting in greatly reduced Pol II occupancy
was shown to involve a loss of P-TEFb [26]. Although the level
and pattern of P-TEFb occupancy in both untreated JQ1 sensitive
and resistant cell types were similar, JQ1 treatment/Brd4
inhibition decreased P-TEFb occupancy only in Raji cells
(Fig. 3). These results indicated levels of BRD4 dependence for
maintaining P-TEFb occupancy vary in different cell lines (Fig. 3).
RNA Pol II Recruitment
We next determined if the difference in JQ1 selectivity was due
to a difference in general transcription apparatus recruitment,
represented by RNA Polymerase II (Pol II). While total Pol II was
greatly decreased across the body of MYC in Raji cells upon JQ1
treatment, it was not altered in the JQ1 resistant BAL17 line
(Fig. 4A). Both cell types showed Pol II occupancy at the P0
promoter, which has been shown to correlate with a very high
level of transcription [34]. Many actively transcribed genes
(including MYC) exhibit paused Pol II at their proximal promoters
[35]. Consistent with this notion, we observed a high level of
promoter-associated Pol II in both cell types, although two-fold
more Pol II was noted at the proximal promoter (roughly
corresponding to the P0 promoter region) in BAL17 (2354)
compared to Raji (2279). Interestingly, as noted with Brd4 and P-
TEFb (Figs. 3 and 4), total Pol II was reduced at a site immediately
downstream (+0.6 kb) of the TSS and sharply increased afterward
(Fig. 4A).
Because phosphorylation of the carboxy-terminal domain
(CTD) of RNA Pol II is associated with regulation of transcription
initiation and elongation at many promoters [36,37], we analyzed
these events in the two cell types in the absence and presence of
JQ1. While RNA Pol II phospho-Ser5 (Pol II S5P) levels in BAL17
cells remained stable after JQ1 treatment, Pol II S5P levels in Raji
cells were sensitive to JQ1 (Fig. 4B). However, surprisingly, Pol II
S5P levels were refractory at P0 and TSS sites (Fig. 4B, right panel)
but sensitive in the latter half of the gene with a small change
starting downstream of the MYC P3 promoter (+2244) and
becoming increasingly sensitive further down the body of the gene.
Whether the substantial amount of Pol II-Ser5P 39 occupancy
shown here is directly due to 39 Brd4 occupancy or an
overabundance of transcription complexes ‘‘backing up’’ resulting
in reduced elongation and subsequent pausing at the 39 terminus is
unknown.
While Ser5 phosphorylation is associated with a competent but
paused Pol II, Ser2 phosphorylation of the Pol II CTD (Pol II S2P)
represents elongating Pol II [37]. In the absence of JQ1, Pol II S2P
occupancy in both cell types occurred across the body of the gene
with peaks at the promoter regions, and the 39 end. Surprisingly,
while promoter- and TSS-associated Pol II S2P levels in Raji cells
were sensitive to JQ1, downstream regions past P3 exhibited no
JQ1 sensitivity until past the 39 UTR (+5472) (Fig. 4C), suggesting
that the majority of fully elongating RNA polymerase II in these
JQ1 sensitive cells was refractory to JQ1. We also observed a JQ1-
dependent increase in Pol II-Ser2P in the BAL17 line and while
this increase was slight at the promoter and TSS regions, it was
very clear at the 39 terminus.
Differences in H3K36me3
One possible way to delineate between upstream and down-
stream effects on Pol II-Ser2 occupancy is to determine the pattern
of tri-methylation of the histone 3 residue lysine 36, H3K36me3,
which is indicative of a recently passing elongating transcription
complex [37]. In BAL17 cells, JQ1 treatment enhanced the
H3K36me3 signals across the gene (Fig. 5). But in Raji cells, JQ1
treatment decreased H3K36me3 from P0 through TSS until the
P3 region. However, beyond P3, the H3K36me3 became
refractory to JQ1 (Fig. 5) as observed with Pol II S2P (Fig. 4C),
suggesting that once RNA Pol II was in elongation mode, it was
Figure 5. Effects of JQ1 on H3K36me3 status. Cells were either untreated or treated with 1 mM of JQ1 for 2 hours. ChIP assays were performed
in duplicate. Each experiment was analyzed in triplicate via real-time PCR, performed twice, and is reported as the mean and standard deviation of
the two experiments.
doi:10.1371/journal.pone.0087003.g005
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insensitive to JQ1. Together, our data showed that MYC harbored
transcription complexes with variable Brd4 dependency in
different cell types and that Brd4 inhibition resulted in a
differential response at the level of transition from pausing to
elongation.
Accessory Transcription Elongation Factors
P-TEFb frequently functions as a subunit of Super Elongation
Complexes (SEC), consisting of P-TEFb and a mixture of one of
three ELL family members, one of two EAF family members, one
of two AF4 family members (AFF1 and AFF4), and either ENL or
AF9 [29,38]. As the SEC family of Pol II elongation factors are
reported to contain the most catalytically active versions of P-
TEFb active in high-level transcription and to regulate a
checkpoint stage of transcription associated with elongation
[29,39,40], we looked at SEC recruitment at MYC in different
cell types. AFF4 is reported to serve as a central binding platform
for elongation factors in many SEC formations and to target MYC
and regulate its expression in cancer cells [39]. The level of AFF4
occupancy in BAL17 cells was low and refractory to JQ1 (Fig. 6A,
top panel) but increased in the presence of JQ1. In contrast, AFF4
recruitment in Raji cells was much greater and sensitive to JQ1.
Although the AFF4 promoter occupancy in Raji cells, particularly
around 2244 site, was variable in the absence of JQ1, it was
significantly decreased in the presence of JQ1. Moreover,
consistent with the Pol II S2P and H3K36me3 results, JQ1
sensitivity was lost past the P3 promoter region (+2244), once again
suggesting that the elongating transcription complex was refrac-
tory to JQ1 (Fig. 6A, bottom panel).
We subsequently looked at occupancy of another SEC
component, ELL2, which has been reported to play a role in
the transition from paused Pol II to elongation [40]. We also tested
occupancy of the Mediator component (MED26) as well as
Gdown1. Though first linked to initiation, a role for Mediator in
recruiting Pol II transcription elongation factors and phosphory-
lation of the Pol II CTD regulating Pol II pausing and elongation
has emerged [41]. The Mediator complex most strongly associated
with Pol II includes MED26, which has been shown to increase
activation of transcription in vitro to a greater degree than other
forms of the Mediator complex and play a key role in SEC
recruitment and MYC transcription [41]. Gdown1 is a Pol II
binding protein shown to be necessary for a Mediator-dependent
response to activation of transcription [42]. More appropriate to
Figure 6. Occupancy of elongation factors at the MYC locus. Cells were either untreated or treated with 1 mM of JQ1 for 2 hours. (A) AFF4 was
detected by ChIP across the length of the MYC gene in both BAL17 and Raji cells. (B) Detection of AFF4, ELL2 and MED26 in the promoter regions of
untreated human HeLa and Raji cells. ChIP assays were performed in duplicate. Each experiment was analyzed in triplicate via real-time PCR,
performed twice, and is reported as the mean and standard deviation of the two experiments.
doi:10.1371/journal.pone.0087003.g006
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this study, Gdown1 has recently been shown to increase the
stability of paused Pol II and regulate P-TEFb activity [28].
Because the available antibodies against ELL2, Med26 and
Gdown1 were species (human) specific, we employed HeLa and
Raji cells for these experiments. Given the differences focused
around the P3 region, we focused on the general promoter region
(P0, TSS, and P3) to test the differences between these cell lines. As
observed for BAL17 cells, HeLa cells exhibited low AFF4
recruitment at this region in comparison to Raji cells (Fig. 6B).
Consistent with AFF4 recruitment results, increased ELL2
occupancy near P3 was seen in Raji cells compared to HeLa
cells. MED26 occupancy showed a pattern similar to that of other
SEC components with an increase, though more modest, near the
P3 promoter in Raji cells (Fig. 6B). Finally, we observed that
Gdown1 followed a pattern similar to that of SEC and Mediator
with an increase around the P3 promoter in Raji cells (Fig. 6B).
Discussion
Due to the importance of MYC in the genesis of hematopoietic
malignancies, intense efforts have been directed for the past two
decades toward understanding its regulation. Yet, given that MYC
overexpression is caused by a plethora of genetic lesions, a uniform
set of rules governing its transcriptional regulation is still missing.
Recent advances in this area include the discovery of a small
molecule inhibitor, JQ1 that decreases MYC expression and is
therapeutically effective in pre-clinical animal models of midline
carcinoma and in BL cells. However, JQ1 does not inhibit MYC
expression to a similar extent in all cancer cells, further
underscoring that MYC transcription is perhaps under different
controls in various cancer cell types. Consistent with this notion,
we discovered that JQ1 inhibits MYC expression in all BL-derived
cells tested but does not inhibit MYC expression in some other
cancer cell lines, as observed earlier (19). Because MYC
deregulation can occur via different modes, we hypothesized that
in distinct lymphoma phenotypes, high-level MYC expression may
come under the controls of different transcriptional and epigenetic
regulatory mechanisms, which may be sensitive or resistant to
JQ1/Brd4 inhibition. In this study, we explored these mechanisms
to establish MYC transcriptional and epigenetic signatures
associated with particular cell types with the hope that these
signatures will better define lymphoma subtypes and provide new
therapeutic avenues to explore for clinically aggressive B cell
lymphomas.
Although BL cells are a heterogeneous lot with differences in the
length of Ig/MYC translocation that reportedly translate to
variable levels of MYC overexpression [43], BL cells in our hands
(Fig. 1 and Figure S1, in File S1), and others [19], are uniformly
susceptible to inhibition of MYC expression via Brd4 inhibition by
JQ1. This inhibition appears to be regardless of whether these are
Figure 7. Proposed Model. (A) Summary of levels of factor occupancy spanning the MYC promoter P0, P1, P2 and P3 regions and associated with
regulation of MYC transcription. (B) Graphical representation of proposed model of MYC transcription elongation regulation under different
conditions–left panel shows non-translocated MYC locus and right panel depicts IGH-MYC translocated locus.
doi:10.1371/journal.pone.0087003.g007
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EBV positive or negative BL lines (our study and ref 19). Brd4 is
primarily associated with 59-end promoters and enhancers
[44,45,46], and while we do see a more prominent level of Brd4
at the TSS in Raji cells (Fig. 2), we also observe Brd4 occupancy
across the body of the MYC gene in JQ1 resistant cells (Fig. 2). One
function of Brd4 is P-TEFb recruitment and P-TEFb occupancy
does parallel Brd4-inhibitor sensitive MYC transcription, despite
the fact that there is little difference in P-TEFb occupancy in
untreated cells of either resistant or sensitive cells. Therefore, it
appears that in cells resistant to JQ1, a Brd4-independent
mechanism operates to recruit or retain P-TEFb and produce
high levels of MYC transcription.
Because the SEC components AFF4 and ELL2 play a role in
MYC regulation and transcriptional elongation, we hypothesized
that an increase in these co-factors might relax Brd4 requirements.
Surprisingly, their increased presence actually correlated with
increased requirements for Brd4 (Fig. 6). The position of increased
SEC components together with MED26 and Gdown1 around the
P3 promoter suggests high transcriptional activity or a regulatory
checkpoint in this region that is not present in cells that are
resistant to JQ1 (summarized in Figure 7). It has been noted that in
BL cells, due to MYC-IG translocation, the otherwise minor P3
promoter often becomes active and correlates with higher MYC
expression [43]. Coupled with the recent demonstration that the
translocated MYC locus harbors super enhancers that are sensitive
to JQ1 [45], this raises the possibility that the mechanism of
transcriptional regulation of MYC involving its native/non-
translocated enhancer is different (Fig. 7B, Figure S2, in File S1).
Regulation of transcription at the MYC minor promoters,
including P3, has been shown to involve the P-TEFb regulator
7SK snRNA, which participates in transformation-dependent
MYC deregulation [47]. 7SK snRNA is a complex of RNA and
proteins such as LARP7 and HEXIM1 that are known to stabilize
P-TEFb in an inactive form [13,14,47]. JQ1 also leads to the
release of P-TEFb from the 7SK snRNP and to HIV gene
expression that involves an increase in AFF4 and ELL2 [48,49].
Moreover, while JQ1 inhibited MYC expression in BL lines tested,
it enhanced BCR stimulated induced transcription of c-fos in these
cells (Figure S1, in File S1). Thus, the effects of Brd4 inhibition by
JQ1 appear more complicated than has been previously antici-
pated.
Much is known about the different MYC promoters and their
possible functions in oncogenesis. BAL17 and HeLa cells may
behave like GLC4 cells, where MYC is transcribed at a high rate
but not grossly rearranged [50]. That MYC transcription in GLC4
is reported to initiate mainly from P1 instead of the P2 promoter
and that this promoter shift seems to overcome transcript
termination at a transcriptional pause site described for Burkitt’s
lymphoma [50]. In the future, it will be interesting to conclusively
determine if any difference in cell-specific primary transcription
and MYC promoter usage is driving, or being driven by, the
differences in transcriptional elongation regulation we report here.
Point mutations could also play a role in differential JQ1 sensitivity
though a search of available UCSC Genome Browser tracks only
finds one SNP reported in the general vicinity of the P1/P2
promoter (data not shown).
Altered regulation at the elongation stage of transcription has
been proposed to contribute to leukemic pathogenesis [29,51].
While many PRGs such as MYC have a well-recognized
checkpoint at +40 to the TSS that is associated with paused
transcription [52,53], our data indicate that an additional potential
checkpoint near the region around P3 may be utilized differently
depending upon the mode of MYC overexpression. In the near
future, we hope to employ different MYC-driven lymphoma
samples to test whether the transcriptional signatures that we
observe here correlate with the particular MYC genetic lesion
(translocated versus non-translocated).
Supporting Information
File S1 File includes Figures S1–S3. Figure S1. Effect of
JQ1 on MYC and Fos expression. (A) Effect of JQ1 on Ramos BL
cell line in the absence of any stimulation. (B) The reported cell
lines were incubated at 37C with 1 mM JQ1 for 2 hours prior to
addition of 10 mM of anti-mouse IgM fragments, which triggers
the B cell receptor (BCR). After 30 minutes stimulation, RNA was
harvested and analyzed for c-fos, c-myc and ActB mRNA
expression as detailed in Materials and Methods. The experiments
were performed in triplicate and reported as the mean and
standard deviation of the ratio of target mRNA over ActB mRNA.
Figure S2. RNA Pol II occupancy at the MYC locus in Raji and
HeLa cells. ChIP-seq data–ENCONDE UCSC Genome Browser
tracks of Polymerase II occupancy at the MYC locus in HeLa and
Raji cells. Figure S3. Primer positions and sequences used for
ChIP across mouse and human MYC locus.
(PDF)
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